RepliCel Life Valuation
| RP Stock | CAD 0.01 0.00 0.00% |
RepliCel Life seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of RepliCel Life Sciences from analyzing the company fundamentals such as Current Valuation of 744.26 K, return on asset of -1.53, and Shares Owned By Insiders of 59.39 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting RepliCel Life's valuation include:
Enterprise Value 744.3 K | Enterprise Value Ebitda (2.78) | Price Sales 2.08 | Enterprise Value Revenue 2.104 |
Overvalued
Today
Please note that RepliCel Life's price fluctuation is out of control at this time. Calculation of the real value of RepliCel Life Sciences is based on 3 months time horizon. Increasing RepliCel Life's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the RepliCel stock is determined by what a typical buyer is willing to pay for full or partial control of RepliCel Life Sciences. Since RepliCel Life is currently traded on the exchange, buyers and sellers on that exchange determine the market value of RepliCel Stock. However, RepliCel Life's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.01 | Real 0.0096 | Hype 0.01 |
The intrinsic value of RepliCel Life's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence RepliCel Life's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of RepliCel Life Sciences helps investors to forecast how RepliCel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of RepliCel Life more accurately as focusing exclusively on RepliCel Life's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use RepliCel Life's intrinsic value based on its ongoing forecasts of RepliCel Life's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against RepliCel Life's closest peers.
RepliCel Life Cash |
|
RepliCel Valuation Drivers Correlation
Many accounts on the financial statements of RepliCel Life Sciences are highly interrelated and sometimes correlated. Consequently, when conducting RepliCel's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of RepliCel
Click cells to compare fundamentals
RepliCel Valuation Trend
Analysing the historical paterns of RepliCel Life's enterprise value and its market capitalization is a good way to estimate and gauge the value of RepliCel Life Sciences over time and is usually enough for investors to make rational market timing decisions.
RepliCel Life Total Value Analysis
RepliCel Life Sciences is at this time estimated to have valuation of 744.26 K with market capitalization of 735.78 K, debt of 813.19 K, and cash on hands of 1.16 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the RepliCel Life fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
744.26 K | 735.78 K | 813.19 K | 1.16 M |
RepliCel Life Investor Information
About 59.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.02. RepliCel Life Sciences last dividend was issued on the 10th of August 2016. The entity had 1:10 split on the 10th of August 2016. Based on the measurements of operating efficiency obtained from RepliCel Life's historical financial statements, RepliCel Life Sciences may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.RepliCel Life Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. RepliCel Life has an asset utilization ratio of 122.92 percent. This indicates that the Company is making C$1.23 for each dollar of assets. An increasing asset utilization means that RepliCel Life Sciences is more efficient with each dollar of assets it utilizes for everyday operations.RepliCel Life Ownership Allocation
RepliCel Life owns a total of 73.58 Million outstanding shares. RepliCel Life has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.RepliCel Life Profitability Analysis
The company reported the previous year's revenue of 353.74 K. Net Loss for the year was (311.73 K) with profit before overhead, payroll, taxes, and interest of 353.74 K.About RepliCel Life Valuation
Our relative valuation model uses a comparative analysis of RepliCel Life. We calculate exposure to RepliCel Life's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of RepliCel Life's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 352.3 K | 374.9 K | |
| Pretax Profit Margin | (0.88) | (0.93) | |
| Operating Profit Margin | (3.92) | (4.11) | |
| Net Loss | (0.88) | (0.93) |
Additional Tools for RepliCel Stock Analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.